The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases including Parkinson’s, a priority indication for the company. The company also aims to expand its proprietary platform to include other diseases, such as other neurodegenerative diseases, macular degeneration, heart disease and cancer.